{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:00:21Z","timestamp":1793746821545,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX09303005"],"award-info":[{"award-number":["2017ZX09303005"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cellimm.2023.104782","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:33:45Z","timestamp":1698986025000},"page":"104782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antitumor activity of pegylated human interferon \u03b2 as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation"],"prefix":"10.1016","volume":"393-394","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-7622","authenticated-orcid":false,"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12929-017-0341-0","article-title":"Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets","volume":"24","author":"Tsai","year":"2017","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.cellimm.2023.104782_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26082278","article-title":"From oncogenic signaling pathways to single-cell sequencing of immune cells: changing the landscape of cancer immunotherapy","volume":"26","author":"Derakhshani","year":"2021","journal-title":"Molecules"},{"issue":"14","key":"10.1016\/j.cellimm.2023.104782_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145034","article-title":"The latest findings of PD-1\/PD-L1 inhibitor application in gynecologic cancers","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cellimm.2023.104782_b0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.it.2018.05.001","article-title":"Defining and Understanding Adaptive Resistance in Cancer Immunotherapy","volume":"39","author":"Kim","year":"2018","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.cellimm.2023.104782_b0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.cellimm.2023.104782_b0045","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10031","key":"10.1016\/j.cellimm.2023.104782_b0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cellimm.2023.104782_b0055","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cellimm.2023.104782_b0060","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"14","key":"10.1016\/j.cellimm.2023.104782_b0065","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons alpha and beta in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.cellimm.2023.104782_b0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0085","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.cellimm.2023.104782_b0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2008.09.004","article-title":"Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis","volume":"14","author":"De Palma","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellimm.2023.104782_b0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.ircmb.2019.06.001","article-title":"Type I interferons and dendritic cells in cancer immunotherapy","volume":"348","author":"Sprooten","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"9633","key":"10.1016\/j.cellimm.2023.104782_b0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cellimm.2023.104782_b0115","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","article-title":"Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma","volume":"17","author":"Herndon","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.cellimm.2023.104782_b0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","article-title":"New perspectives on type I IFNs in cancer","volume":"26","author":"Gajewski","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/excr.1998.4329","article-title":"Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines","volume":"247","author":"Zhang","year":"1999","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0130","first-page":"2635","article-title":"IFN-beta sensitizes TRAIL-induced apoptosis by upregulation of death receptor 5 in malignant glioma cells","volume":"42","author":"Yoshimura","year":"2019","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2015.12.027","article-title":"Alpha and beta type 1 interferon signaling: passage for diverse biologic outcomes","volume":"164","author":"Ng","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2023.104782_b0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fimmu.2014.00073","article-title":"Combinatorial cytokine code generates anti-viral state in dendritic cells","volume":"5","author":"Hartmann","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0145","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.1038\/s41598-017-12414-3","article-title":"The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis","volume":"7","author":"Enomoto","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cellimm.2023.104782_b0150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: an update","volume":"33","author":"Varyte","year":"2021","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.cellimm.2023.104782_b0155","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon beta for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"7","key":"10.1016\/j.cellimm.2023.104782_b0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/ced.13179","article-title":"Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis","volume":"42","author":"Yanagi","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000336490","article-title":"Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study","volume":"82","author":"Aoyagi","year":"2012","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.cellimm.2023.104782_b0170","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jjco\/hyx063","article-title":"Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II\/III cutaneous melanoma: japan clinical oncology group study (JCOG1309, J-FERON)","volume":"47","author":"Namikawa","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"41","key":"10.1016\/j.cellimm.2023.104782_b0180","doi-asserted-by":"crossref","first-page":"71181","DOI":"10.18632\/oncotarget.17090","article-title":"Phase I study of nivolumab combined with IFN-beta for patients with advanced melanoma","volume":"8","author":"Fujimura","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.cellimm.2023.104782_b0185","doi-asserted-by":"crossref","first-page":"e1047584","DOI":"10.1080\/2162402X.2015.1047584","article-title":"Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages","volume":"4","author":"Kakizaki","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.cellimm.2023.104782_b0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbrc.2017.06.072","article-title":"Intratumoral injection of IFN-beta induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb","volume":"490","author":"Uehara","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/11596970-000000000-00000","article-title":"PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis","volume":"26","author":"Kieseier","year":"2012","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0200","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00183-17","article-title":"Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus","volume":"61","author":"Tsuge","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0205","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.28551","article-title":"CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta","volume":"134","author":"Jablonska","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0210","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1189\/jlb.1205742","article-title":"Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression","volume":"79","author":"Severa","year":"2006","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0215","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cyto.2010.01.009","article-title":"Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"50","author":"Antonelli","year":"2010","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.cellimm.2023.104782_b0220","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/ane.13400","article-title":"Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-beta treatment","volume":"143","author":"Zhukovsky","year":"2021","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.cellimm.2023.104782_b0225","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jir.2010.0054","article-title":"Gene regulatory and clinical effects of interferon beta in patients with metastatic melanoma: a phase II trial","volume":"31","author":"Borden","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"issue":"29","key":"10.1016\/j.cellimm.2023.104782_b0230","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.2174\/138161212802502215","article-title":"An inventory of short term and long term changes in gene expression under interferon beta treatment of relapsing remitting MS patients","volume":"18","author":"Paap","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"19","key":"10.1016\/j.cellimm.2023.104782_b0235","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104782_b0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13000-015-0431-9","article-title":"A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"10","author":"Uguen","year":"2015","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.cellimm.2023.104782_b0245","unstructured":"Blast. Available from: https:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0250","doi-asserted-by":"crossref","first-page":"e84259","DOI":"10.1371\/journal.pone.0084259","article-title":"Bridging the species divide: transgenic mice humanized for type-I interferon response","volume":"9","author":"Harari","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.cellimm.2023.104782_b0255","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.cellimm.2023.104782_b0265","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/jir.1996.16.777","article-title":"Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma","volume":"16","author":"Fierlbeck","year":"1996","journal-title":"J. Interferon Cytokine Res."},{"issue":"14","key":"10.1016\/j.cellimm.2023.104782_b0270","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.ejca.2011.12.009","article-title":"Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs","volume":"48","author":"Song","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cellimm.2023.104782_b0275","doi-asserted-by":"crossref","first-page":"1047610","DOI":"10.3389\/fimmu.2022.1047610","article-title":"PD-1\/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2023.104782_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040711","article-title":"Natural killer cells and anti-cancer therapies: reciprocal effects on immune function and therapeutic response","volume":"13","author":"Toffoli","year":"2021","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.cellimm.2023.104782_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957119","article-title":"Editorial: innate anti-tumor immune responses in solid and hematological malignancies: from basic research to clinical applications","volume":"13","author":"Chretien","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cellimm.2023.104782_b0290","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0295","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2015.02.012","article-title":"Immune checkpoint blockade and interferon-alpha in melanoma","volume":"42","author":"Rafique","year":"2015","journal-title":"Semin. Oncol."},{"issue":"11","key":"10.1016\/j.cellimm.2023.104782_b0300","doi-asserted-by":"crossref","first-page":"e044036","DOI":"10.1136\/bmjopen-2020-044036","article-title":"Phase I\/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial","volume":"10","author":"van der Kooij","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.cellimm.2023.104782_b0305","doi-asserted-by":"crossref","unstructured":"Najjar, Y.G., D. McCurry, and H. Lin, Neoadjuvant Pembrolizumab and High-Dose IFN\u03b1-2b in Resectable Regionally Advanced Melanoma. 2021. 27(15): p. 4195-4204. http:\/\/doi.org\/10.1158\/1078-0432.ccr-20-4301.","DOI":"10.1158\/1078-0432.CCR-20-4301"},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0310","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-018-0428-5","article-title":"Neoadjuvant ipilimumab (3 mg\/kg or 10 mg\/kg) and high dose IFN-alpha2b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellimm.2023.104782_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.735133","article-title":"IFNbeta Is a potent adjuvant for cancer vaccination strategies","volume":"12","author":"Audsley","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2023.104782_b0320","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/mthe.2001.0464","article-title":"Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models","volume":"4","author":"Qin","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2023.104782_b0325","doi-asserted-by":"crossref","unstructured":"Rajendran, R. and V. Rajendran, Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis. 2022. 23(20). http:\/\/doi.org\/10.3390\/ijms232012183.","DOI":"10.3390\/ijms232012183"},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cgt.7700878","article-title":"Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta","volume":"13","author":"Streck","year":"2006","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0335","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12864-019-6344-3","article-title":"Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors","volume":"21","author":"Zhong","year":"2020","journal-title":"BMC Genomics"},{"key":"10.1016\/j.cellimm.2023.104782_b0340","doi-asserted-by":"crossref","unstructured":"Tseng, S.H., et al., Albumin and interferon-\u03b2 fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. 2022. 10(4). http:\/\/doi.org\/10.1136\/jitc-2021-004342.","DOI":"10.1136\/jitc-2021-004342"},{"issue":"1","key":"10.1016\/j.cellimm.2023.104782_b0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","article-title":"Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer","volume":"159","author":"Ma","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cellimm.2023.104782_b0350","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1096\/fj.201700740R","article-title":"Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy","volume":"32","author":"Wang","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.cellimm.2023.104782_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114112","article-title":"Engineering interferons and interleukins for cancer immunotherapy","volume":"182","author":"Holder","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"36","key":"10.1016\/j.cellimm.2023.104782_b0360","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205983119","article-title":"Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies","volume":"119","author":"Lutz","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874923001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874923001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T18:24:51Z","timestamp":1762107891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874923001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":72,"alternative-id":["S0008874923001211"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2023.104782","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity of pegylated human interferon \u03b2 as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2023.104782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104782"}}